drugset / Trial / NCT07613528

Individualized Prolonged Luteal Support After Fresh Embryo Transfer in Women With Low Progesterone

NCT07613528

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to compare live birth rate in a control group versus an interventional group in subjects aged 18 to 37, pregnant after a fresh embryo transfer and with a serum progesterone level below 17 ng/mL on the day of pregnancy test while using vaginal progesterone as a luteal support. . This is the first randomized controlled trial to assess the benefit of prolonged subcutaneous progesterone administration in patients with a positive pregnancy test (Bêta chorionique gonadotropic hormone: β-hCG \>100 IU/L) after fresh transfer and low progesterone level (\<17 ng/mL). Half the participants will be offered a an extension of luteal phase support , by subcutaneous progesterone supplementation for 6 weeks, the other half will have placebo injections. A double-blind, placebo-controlled, randomized design was chosen to prevent selection bias and ensure the comparability of both study arms.

Timeline

Start
2027-03
Primary completion
2029-09
Completion
2030-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Progesterone Other / unclassified 25 mg Subcutaneous
Background Progesterone Other / unclassified 200 mg Intravenous

Indications